Market Overview
Price Performance
Market Snapshot
Earnings & Events
Recent Earnings
2026-08-12
EPS: -0.08
Est: -0.07
Surprise: -0.01
Miss
2026-05-14
EPS: -0.11
Est: -0.07
Surprise: -0.04
Miss
2026-03-30
EPS: 0
Est: -0.075
Surprise: 0.08
Beat
2025-11-12
EPS: -0.14
Est: -0.07
Surprise: -0.07
Miss
Recent SEC Filings
Company Press Releases
- Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
- Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
- Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
- Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
- Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
Resources
- Company Website
- Investor Relations Contact: John Patton
- Corporate Presentation
- SEC Profile
- Symbol: NASDAQ: ONCY
Summary
Company Overview
Oncolytics Biotech® Inc. is a clinical-stage biotechnology company developing innovative immunotherapy solutions for cancer treatment. The company’s lead product candidate, pelareorep, is an intravenously delivered oncolytic virus designed to selectively replicate in cancer cells while stimulating anti-tumor immune responses.
The company’s development strategy emphasizes combination therapies that enhance the effectiveness of existing cancer treatments, including immune checkpoint inhibitors and chemotherapy.
Business Highlights
- Clinical-stage biotechnology company focused on cancer immunotherapy
- Lead product candidate pelareorep evaluated across multiple oncology indications
- Strategy centered on combination therapies with existing cancer treatments
- Clinical programs conducted with global research partners
- Publicly traded on NASDAQ under the ticker ONCY
Key Portfolio Considerations
- Exposure to oncology immunotherapy via a differentiated oncolytic virus platform
- Clinical-stage profile with value creation driven by trial milestones
- Potential upside through partnerships and regulatory progress
- Ongoing capital market engagement supports long-term growth initiatives
- May suit portfolios seeking asymmetric risk–reward biotechnology exposure
Summary
Company Overview
Oncolytics Biotech® Inc. is a clinical-stage biotechnology company developing innovative immunotherapy solutions for cancer treatment. The company’s lead product candidate, pelareorep, is an intravenously delivered oncolytic virus designed to selectively replicate in cancer cells while stimulating anti-tumor immune responses.
The company’s development strategy emphasizes combination therapies that enhance the effectiveness of existing cancer treatments, including immune checkpoint inhibitors and chemotherapy.
Business Highlights
- Clinical-stage biotechnology company focused on cancer immunotherapy
- Lead product candidate pelareorep evaluated across multiple oncology indications
- Strategy centered on combination therapies with existing cancer treatments
- Clinical programs conducted with global research partners
- Publicly traded on NASDAQ under the ticker ONCY
Key Portfolio Considerations
- Exposure to oncology immunotherapy via a differentiated oncolytic virus platform
- Clinical-stage profile with value creation driven by trial milestones
- Potential upside through partnerships and regulatory progress
- Ongoing capital market engagement supports long-term growth initiatives
- May suit portfolios seeking asymmetric risk–reward biotechnology exposure
Chart Data
Company Press Releases
Company Press Releases
- Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
- Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
- Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
- Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
- Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
Recent Earnings
2026-08-12
EPS: -0.08
Est: -0.07
Surprise: -0.01
Miss
2026-05-14
EPS: -0.11
Est: -0.07
Surprise: -0.04
Miss
2026-03-30
EPS: 0
Est: -0.075
Surprise: 0.08
Beat
2025-11-12
EPS: -0.14
Est: -0.07
Surprise: -0.07
Miss
AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033
BullishBattery Storage Market Size Projected to Reach $105.96 Billion By 2030
BullishUtilities Are Short Billions of Pounds of Uranium They Haven't Bought Yet, and the Math Is Getting Harder Every Year
BullishGlobal Tungsten Market Size Projected to Reach $9.62 Billion By 2030
BullishGlobal Post-Quantum Cryptography Market Size Projected to Reach $2.84 Billion By 2030
BullishThe AI Buildout Runs on Power and Cooling. Bitzero Just Deepened Its Bench With Vertiv.
BullishThe Infrastructure Under America's Busiest Spaceport Was Built for Another Era. New Legislation Would Let Private Companies Help Modernize It.
BullishTwo Years of Surface Work. Three Priority Targets. Now the Drills Are Permitted in One of the World's Last Undrilled Epithermal Districts.
BullishEagle Nuclear Energy Corp. Holds the Rights to the Largest conventional, measured and indicated uranium Deposit in the USA, and It's Systematically Advancing It Toward Development
BullishNew Zealand Just Handed RUA GOLD a Six-Month Permitting Clock: The Drills, the Studies, and the Community are Ready
BullishLatest Company News
-
Form 8K Oncolytics Biotech Inc. For: 29 September By Investing.com
This article reports on Oncolytics Biotech Inc.'s Form 8K filing for September 29. The filing pertains to the company ONCY, which saw a 1.66% increase. The article mentions the publication date as September 29, 2026, at 10:12 a.m.
-
Oncolytics Reports Pelareorep Liver Cancer Research Findings
Oncolytics Biotech reported preclinical findings indicating that its investigational oncolytic virus therapy, pelareorep, increased immune activity markers in hepatocellular carcinoma models. The study, published in the Proceedings of the National Academy of Sciences, showed increased PD-L1 expression, ICOSL levels, and CD8+ T-cell density in liver cancer tumors, suggesting pelareorep could enhance responsiveness to immune-based treatments. However, the company emphasized that these are preclinical results and it currently does not plan to pursue liver cancer as an indication for pelareorep.
-
Form 8K Oncolytics Biotech Inc. For: 29 September By Investing.com
This article reports that Oncolytics Biotech Inc. filed a Form 8K on September 29, 2026. The Form 8K is a crucial document that companies file with the SEC to announce significant events that shareholders should know about. The brief piece indicates this filing is available for review, likely containing important company updates.
-
Form 8K Oncolytics Biotech Inc. For: 29 September By Investing.com
This article reports on Oncolytics Biotech Inc.'s Form 8K filing for September 29. The filing details are not provided in the snippet, but the article contextualizes it within broader market movements and offers financial data for various indices and commodities.
-
Oncolytics reports pelareorep data in liver cancer study
Oncolytics Biotech Inc. announced that preclinical data on its investigational immunotherapy, pelareorep, was published, demonstrating its ability to alter the tumor microenvironment in liver cancer. The study showed that pelareorep increased PD-L1 expression and CD8+ T cell density, suggesting a shift from an immunologically inactive to an active state. Although liver cancer is not a current focus, the company notes pelareorep's potential to enhance other anti-cancer therapies and is seeking strategic partnerships for development, especially since it has Fast Track designation for several gastrointestinal cancers.
Media Hub
Real-time press releases, oncology news, and market commentary
Equity Insider
Oct 1, 2026
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
Bullish
Equity Insider
Sep 29, 2026
Tanzania Gold Exports Climb 37% as East African Mine Builds Advance
Bullish
Equity Insider
Sep 28, 2026
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
Bullish
Equity Insider
Sep 25, 2026
Today's Stolen Data Could Be Tomorrow's Decrypted Data
Bullish
Equity Insider
Sep 24, 2026
West Coast Refinery Closures Put Nevada's Fuel Supply Under Pressure
Bullish
Equity Insider
Sep 22, 2026
Energized Power Capacity Is Shaping the Next Phase of AI Infrastructure
Bullish
Equity Insider
Sep 17, 2026
By-Product Credits Can Push a Silver Mine's Cash Cost Below Zero
Bullish
Equity Insider
Sep 17, 2026
Satellites Built Today Must Outlive the Encryption Protecting Them
Bullish
Equity Insider
Sep 16, 2026
Gold Is Near Record Highs, The Slow Part Is Buying the Surface
Bullish
Equity Insider
Sep 10, 2026
Diesel Sets a Record $5.90 a Gallon as the Generator Market Heads Toward $25.6 Billion
Bullish
Equity Insider
Sep 10, 2026
Mines Do Not Usually Fail on Geology. They Stall on Land Access
Bullish
Equity Insider
Sep 9, 2026
Global Uranium Market Projected to Reach $13.59 Billion by 2033 as Washington Becomes the Sector's Largest Counterparty
BullishResources
- Company Website
- Investor Relations Contact: John Patton
- Presentation
- SEC Profile
- Symbol: NASDAQ: ONCY
Key Portfolio Considerations
- Exposure to oncology immunotherapy via a differentiated oncolytic virus platform
- Clinical-stage profile with value creation driven by trial milestones
- Potential upside through partnerships and regulatory progress
- Ongoing capital market engagement supports long-term growth initiatives
- May suit portfolios seeking asymmetric risk–reward biotechnology exposure
